US Biosimilars Watch: Similar but not déjà vu
Biosimilars, or follow-on biologics, have the potential to offer safe and effective treatment at a lower cost than a reference biologic. But despite great anticipation, biosimilars have seen relatively slow growth in the USA.
Moving forward, we can apply many lessons learned from generic small molecule drugs, which similarly faced slow growth in the 1980s and yet currently account for nearly 90% of prescriptions in the USA. Nevertheless, the additional regulatory, legal, scientific, and public perception issues unique to biosimilars will create new challenges.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available on our about page.
AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 23 percent of total drug spending. Additional information is available at www.accesiblemeds.org.